Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with high-risk early triple-negative breast cancer, using pembrolizumab with chemotherapy before surgery and pembrolizumab alone afterward.
LAMPGEN ANALYSIS
Why it matters
The regimen spans preoperative treatment and postoperative continuation in high-risk early disease.
What research teams should watch
Coordinate neoadjuvant cycles, surgery, pathology and adjuvant restart dates.
PRIMARY RECORDS